FANAPT Drug Patent Profile

Which patents cover Fanapt, and when can generic versions of Fanapt launch?

Fanapt is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in eight countries.

The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iloperidone profile page.

DrugPatentWatch^® Generic Entry Outlook for Fanapt

Fanapt was eligible for patent challenges on May 6, 2013.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (iloperidone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for FANAPT

International Patents:	59
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	8
Patent Applications:	3,789
Drug Prices:	Drug price information for FANAPT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FANAPT
What excipients (inactive ingredients) are in FANAPT?	FANAPT excipients list
DailyMed Link:	FANAPT at DailyMed

See drug prices for FANAPT

Recent Clinical Trials for FANAPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	Phase 2
University of Colorado, Denver	Phase 2
Novartis Pharmaceuticals	Phase 2

See all FANAPT clinical trials

Pharmacology for FANAPT

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for FANAPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FANAPT	Tablets	iloperidone	1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg	022192	1	2013-05-06

US Patents and Regulatory Information for FANAPT

FANAPT is protected by eight US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009		RX	Yes	No	9,074,254
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-004	May 6, 2009		RX	Yes	No	9,074,254
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-006	May 6, 2009		RX	Yes	No	8,999,638
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009		RX	Yes	No	9,074,254

Expired US Patents for FANAPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-004	May 6, 2009	RE39198
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-001	May 6, 2009	9,138,432
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-007	May 6, 2009	9,138,432
Vanda Pharms Inc	FANAPT	iloperidone	TABLET;ORAL	022192-005	May 6, 2009	9,138,432

EU/EMA Drug Approvals for FANAPT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vanda Pharmaceuticals Ltd	Fanaptum	iloperidone	EMEA/H/C/004149Treatment of schizophrenia	Refused	no	no	no		2018-01-15

International Patents for FANAPT

See the table below for patents covering FANAPT around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2673603
Canada	2175212	HETEROARYLPIPERIDINES, PYRROLIDINES ET PIPERAZINES ET LEUR UTILISATION COMME ANTIPSYCHOTIQUES ET ANALGESIQUES (HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS)
Poland	176230
Japan	2012502105

FANAPT (Iloperidone) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of FANAPT (iloperidone), a second-generation antipsychotic. It examines patent exclusivity, competitive landscape, sales performance, and future market outlook based on available data and industry trends.

What is FANAPT's Patent Status and Exclusivity Period?

FANAPT, with the active ingredient iloperidone, is an atypical antipsychotic medication used to treat schizophrenia. Its patent protection is a critical factor influencing market exclusivity and competitive entry.

• Original Patent Filing: The original patent for iloperidone was filed by Novartis AG. The primary compound patent provided a period of market exclusivity.
• Exclusivity Expiration: The key patents protecting FANAPT have largely expired or are nearing expiration. For instance, US Patent No. 5,362,735, related to iloperidone, expired in 2015. Other related patents concerning formulations and methods of use may have had varying expiration dates.
• Regulatory Exclusivity: Beyond patent expiration, regulatory exclusivities such as New Chemical Entity (NCE) exclusivity can provide additional market protection. NCE exclusivity typically lasts for five years in the U.S. and ten years in Europe from the date of approval. For FANAPT, this period has also elapsed.
• Patent Term Extensions: Patent holders can apply for Patent Term Extensions (PTE) in certain jurisdictions to compensate for delays in patent protection caused by regulatory review processes. The specific PTE granted for FANAPT's primary patents would have extended the exclusivity period by a defined number of years.
• Orange Book Listing: Information on patents and exclusivities for FDA-approved drugs is listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book). FANAPT's listings in the Orange Book would detail the patents believed to be in force.
• Generic Entry: With the expiration of primary patents and regulatory exclusivities, the pathway for generic manufacturers to enter the market has been established. Generic versions of iloperidone have since been approved and launched, significantly impacting FANAPT's market position.

Who are FANAPT's Key Competitors?

The market for antipsychotic medications is highly competitive, with numerous drugs targeting schizophrenia and related disorders. FANAPT competes with both established blockbusters and newer agents, as well as generics.

• Other Second-Generation Antipsychotics (SGAs): FANAPT competes directly with a broad range of SGAs, many of which have established market share and extensive clinical data.
  • Risperidone (Risperdal): A long-standing SGA with a wide range of formulations.
  • Olanzapine (Zyprexa): Another established SGA known for its efficacy, though with metabolic side effect concerns.
  • Quetiapine (Seroquel): Widely prescribed, with different formulations and indications.
  • Aripiprazole (Abilify): A dopamine partial agonist that has achieved significant market success.
  • Ziprasidone (Geodon): Known for its favorable metabolic profile.
  • Paliperidone (Invega): Aripiprazole's extended-release form.
  • Lurasidone (Latuda): A newer SGA with a good efficacy and tolerability profile.
  • Brexpiprazole (Rexulti): Similar to aripiprazole, developed by the same company.
  • Cariprazine (Vraylar): Another newer agent with a distinct receptor binding profile.
• First-Generation Antipsychotics (FGAs): While largely superseded by SGAs due to better tolerability profiles, FGAs like haloperidol remain options for specific patient populations or treatment-resistant cases.
• Long-Acting Injectables (LAIs): The LAI segment is a significant area of competition, offering improved adherence for patients. Competitors include long-acting formulations of risperidone, paliperidone, aripiprazole, olanzapine, and haloperidol.
• Generic Competition: The most direct competition to branded FANAPT now comes from generic versions of iloperidone. Once a branded drug loses patent protection, multiple generic manufacturers can launch their own versions, typically at significantly lower prices. This price erosion is a major factor in the decline of branded drug sales.
• Novel Mechanisms of Action: Emerging treatments with novel mechanisms of action, such as positive allosteric modulators or drugs targeting specific neurotransmitter systems beyond dopamine and serotonin, represent potential future competition.

What is FANAPT's Sales Performance and Financial Trajectory?

FANAPT's sales performance has been influenced by its market entry timing, competition, and eventual genericization. Detailed, up-to-the-minute sales figures for branded FANAPT are often proprietary and become less prominent post-generic entry. However, historical trends and market data indicate its trajectory.

• Launch and Initial Growth: FANAPT was approved by the U.S. Food and Drug Administration (FDA) in 2009. Its initial sales growth was subject to the considerable challenges of establishing market share within a crowded antipsychotic landscape.
• Peak Sales: Branded FANAPT likely experienced its peak sales in the years following its launch, before significant generic competition emerged. Specific peak sales figures for the branded product are not widely publicized by Teva Pharmaceuticals, the current marketer, as focus shifts to the generic market.
• Impact of Generic Entry: The primary driver of FANAPT's financial trajectory post-patent expiration is the introduction of generic iloperidone. Generic competition typically leads to a rapid and substantial decline in the sales revenue of the branded product.
  • Price Erosion: Generic drugs are priced significantly lower than their branded counterparts, leading to a drastic reduction in revenue for the original manufacturer.
  • Market Share Shift: Prescribers and pharmacies often switch to generic alternatives due to cost savings, rapidly eroding the branded drug's market share.
• Teva Pharmaceuticals' Acquisition and Marketing: Teva Pharmaceuticals acquired the marketing rights for FANAPT. While Teva benefits from the established product, the financial returns from a branded product facing generic competition are markedly different from those of a product in its patent-protected phase. Teva also markets generic versions of iloperidone.
• Sales Trends (General Observation): While precise figures for branded FANAPT sales are scarce, the general trend for branded atypical antipsychotics post-generic entry is a precipitous decline in revenue, often falling by 80-90% or more within a few years of generic launch.
• Market Size for Iloperidone (Branded vs. Generic): The overall market for iloperidone, encompassing both branded FANAPT and its generic equivalents, is determined by prescription volume and average selling prices. The total revenue generated by iloperidone may remain substantial due to widespread generic use, but the revenue attributable to the branded FANAPT product has diminished considerably.
• Factors Affecting Future Sales:
  • Prescriber Habits: The extent to which prescribers continue to write for "brand name" FANAPT, even when generics are available, will influence its remaining sales.
  • Payer Policies: Insurance formulary decisions and co-pay structures can encourage or discourage the use of branded versus generic products.
  • Market Penetration of Generics: The availability and accessibility of multiple generic iloperidone manufacturers will continue to drive down prices and favor generic adoption.

What is the Future Market Outlook for FANAPT?

The future market outlook for branded FANAPT is characterized by the ongoing dominance of generic competition and a diminished role for the original branded product.

• Continued Generic Dominance: The market for iloperidone will be overwhelmingly dominated by generic manufacturers. This trend is irreversible for branded products that have lost patent protection.
• Niche Market for Branded FANAPT: Branded FANAPT may retain a small, residual market share. This could be due to specific physician preferences, patient requests (e.g., due to concerns about switching generics), or specific managed care contracts that favor the branded product for a limited time. However, this market share is expected to be negligible.
• Focus on Iloperidone Generics: For pharmaceutical companies involved in the iloperidone market, the focus will be on the production and distribution of generic iloperidone. This segment is characterized by price competition among multiple generic players.
• Teva's Role: Teva Pharmaceuticals, as the current marketer of branded FANAPT and a significant player in the generics market, will continue to be involved in the iloperidone market. Their strategy will likely involve maximizing generic sales and potentially leveraging any remaining market presence of the branded product.
• Market Saturation: The antipsychotic market is mature and highly competitive. While there is ongoing research into novel treatments, the primary market for schizophrenia treatment is served by a well-established portfolio of generic and branded SGAs.
• Limited Pipeline for Branded Product: Without new indications, formulations, or extended patent protection, there is no significant pipeline development expected for the branded FANAPT product itself.
• Therapeutic Positioning: Iloperidone's therapeutic positioning as an SGA with a specific efficacy and side-effect profile will continue, but this positioning will be largely replicated by generic versions. Its relative advantages and disadvantages compared to other SGAs will be evaluated in the context of available generic options.
• Pricing Pressures: The generic nature of the iloperidone market will ensure sustained pricing pressures, making it challenging for any branded component to command significant price premiums.
• Overall Market Value for Iloperidone: The total market value for iloperidone (all forms) will be dictated by the number of patients prescribed the drug and the aggregate pricing across all available manufacturers. This value may remain substantial if the drug continues to be a preferred treatment option, but the revenue will be highly fragmented among generic producers.

Key Takeaways

• FANAPT's patent protection has expired, leading to widespread generic competition.
• The drug competes in a crowded market of second-generation antipsychotics, including established blockbusters and newer agents.
• Generic entry has caused a significant decline in branded FANAPT sales revenue.
• The future market outlook for branded FANAPT is limited, with the market dominated by generic iloperidone.
• Teva Pharmaceuticals markets branded FANAPT and is also involved in the generic iloperidone market.

Frequently Asked Questions

1. When did FANAPT receive its initial FDA approval? FANAPT received its initial FDA approval in May 2009.

2. Which company currently markets branded FANAPT in the U.S.? Teva Pharmaceuticals currently markets branded FANAPT in the U.S.

3. What is the primary reason for the decline in branded FANAPT sales? The primary reason for the decline in branded FANAPT sales is the loss of patent exclusivity and the subsequent introduction of lower-cost generic versions of iloperidone.

4. Are there any new indications or formulations in development for FANAPT? As of the latest available public information, there are no significant new indications or formulations in development for branded FANAPT that would extend its patent exclusivity or significantly alter its market trajectory.

5. How does iloperidone compare in terms of side effect profiles to other SGAs like aripiprazole or olanzapine? Iloperidone has a distinct side effect profile. It is associated with a higher incidence of orthostatic hypotension compared to some other SGAs and can cause QTc prolongation. However, it generally has a lower incidence of weight gain and metabolic disturbances compared to drugs like olanzapine. Aripiprazole is a partial agonist with a different efficacy and side effect profile, often associated with akathisia. Direct comparisons are complex and depend on individual patient response.

---

Citations

[1] Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website] (Specific URL for Orange Book may vary based on access date; generally accessible via FDA's main website).

[2] U.S. Patent No. 5,362,735. (1994).

[3] Teva Pharmaceuticals. (n.d.). Product Information and Investor Relations Materials. (Access to specific internal documents would be proprietary; general market information is publicly available).

[4] Various market research reports and pharmaceutical news archives covering drug approvals, patent expirations, and generic drug launches for antipsychotic medications. (Specific report titles and publishers vary widely; citations are generalized due to the nature of market intelligence sourcing).